Allarity Therapeutics
ALLR | NASDAQ
$0.88
-$0.07 (-7.74%)
At close: Nov 16, 2026, 4:00 PM ET
$0.94
+$0.06 (+6.41%)
After-hours:
Nov 16, 2026, 7:40 PM ET
Allarity Therapeutics Company Profile
Company profile explainedCompany Profile
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Thomas H. Jensen | Founder, Chief Executive Officer & Director |
| Jeffrey S. Ervin | Chief Financial Officer |
| Jeremy R. Graff | President & Chief Development Officer |
| Jose L. Iglesias | Consultant Chief Medical Officer |
| Steen Meier Knudsen | Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 424B5 | Filing |
| Oct 30, 2026 | 8-K | Current Report |
| Oct 09, 2026 | 4 | Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Jul 01, 2026 | 8-K | Current Report |
Allarity Therapeutics
| Country | United States |
| IPO Date | Dec 21, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Thomas H. Jensen |
Contact Details
123 E. Tarpon Ave. Tarpon Springs,
Florida 34689 United States
Stock Details
| Ticker Symbol | ALLR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860657 |
| CUSIP Number | 016744500 |
| ISIN Number | US0167445008 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ALLR